Project Grant R43DK100251

This $856,625 Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports an exploratory randomized controlled trial (RCT) of the effects of oral semaglutide on alcohol craving and consumption. The University of Colorado-Denver, as the prime awardee, will conduct this 2-year study to assess the safety, tolerability, and efficacy of semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, compared to placebo...

This federal Project Grant award of $766,877 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund a pragmatic, randomized controlled trial to determine the efficacy of therapeutic drug monitoring (TDM) in preventing premature discontinuation of the antibiotic linezolid in the treatment of rifampin-resistant tuberculosis (RR-TB). The study will enroll 280 RR-TB patients in South Africa and randomize them to receive...

This Cooperative Agreement award from the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $1,837,093.00 in funding to Baylor College of Medicine to conduct a comprehensive evaluation of the abuse potential and pharmacokinetic profile of kratom, an herbal substance with opioid-like properties, in human subjects. The study will employ a rigorous, randomized, double-blind, crossover design involving 60 non-treatment seeking recreational opioid users. The...

The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $962,517 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Public Health Foundation Enterprises, Inc. (Heluna Health) to conduct a two-phase study on the use of the GLP-1 agonist semaglutide for treating methamphetamine use disorder (MEUD). The first phase will be an open-label, single-arm Phase IIA trial to evaluate the eligibility, adherence, and...

This Project Grant award from the Department of Health and Human Services National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $115,000.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the potential role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in improving cardiovascular and kidney outcomes for patients with Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. The...

This $570,362 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) is funding research to evaluate the disease-modifying potential of dimethyl fumarate (DMF) for preventing and treating pharmacoresistant epilepsy. The research aims to determine the pharmacokinetic/pharmacodynamic relationship of DMF, demonstrate stable blood and brain levels using an...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to comparatively assess the therapeutic potential of combined anabolic therapy versus the current standard-of-care single-drug approach in postmenopausal women at high risk of fragility fracture. The $1,175,680 award, with a performance period from September 2024 to August 2027, will be used by...

This Project Grant award of $396,250 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, will support research at Vanderbilt University to investigate the regulation of metabotropic glutamate receptor (mGluR) activity by protein-protein interactions. The research aims to: 1) test a suite of agonists, positive allosteric modulators (PAMs), and negative allosteric modulators (NAMs) for activity at mGluR7 with and without the protein...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $774,930.00 to the Regents of the University of Minnesota to develop and validate a mouse model of intervertebral disc degeneration-induced low back pain. The goal is to create a clinically representative preclinical model that can facilitate the discovery of novel non-addictive analgesics for the treatment of discogenic low...